WeTrials
Completed

A Phase 3, Randomized, Observer-blind, Active-controlled, Case-driven Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared With a Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years of Age

What is this study?

This study is testing an experimental mRNA flu vaccine called mRNA-1010 to see how well it protects adults aged 50 and older compared to standard licensed flu shots. Researchers want to know if this new vaccine is safe and effective at preventing the flu.

Who can participate?

Adults who are 50 years of age or older and willing to follow study rules may be able to join. You cannot participate if you currently have a fever, recent flu exposure, a weakened immune system, or certain unstable medical conditions.

What will happen?

Participants will receive either the experimental mRNA flu vaccine or a standard flu shot to compare their safety and effectiveness. The study team will closely monitor your health and check for any side effects or flu symptoms.

Where and when?

This completed study took place at multiple locations in Alabama, United States. While this specific study is now completed, it helps pave the way for future vaccine developments.

Key Points
  • 1Testing an experimental mRNA flu vaccine against standard flu shots
  • 2Open to adults aged 50 and older who meet health requirements
  • 3Compares how well the vaccines prevent flu symptoms and ensure safety

Related video

JAMA Medical News: what to know about the newly approved mRNA flu vaccine mFLUSIVA (August 2026)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Seasonal Influenza

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.